SG10201403869TA - Organoarsenic compounds and methods for the treatment of cancer - Google Patents

Organoarsenic compounds and methods for the treatment of cancer

Info

Publication number
SG10201403869TA
SG10201403869TA SG10201403869TA SG10201403869TA SG10201403869TA SG 10201403869T A SG10201403869T A SG 10201403869TA SG 10201403869T A SG10201403869T A SG 10201403869TA SG 10201403869T A SG10201403869T A SG 10201403869TA SG 10201403869T A SG10201403869T A SG 10201403869TA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
methods
organoarsenic compounds
organoarsenic
Prior art date
Application number
SG10201403869TA
Other languages
English (en)
Inventor
Brian Eric Schwartz
Jonathan Lewis
Philip B Komarnitsky
Original Assignee
Solasia Pharma K K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solasia Pharma K K filed Critical Solasia Pharma K K
Publication of SG10201403869TA publication Critical patent/SG10201403869TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG10201403869TA 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer SG10201403869TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18951108P 2008-08-20 2008-08-20

Publications (1)

Publication Number Publication Date
SG10201403869TA true SG10201403869TA (en) 2014-10-30

Family

ID=41707414

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201810449XA SG10201810449XA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201403869TA SG10201403869TA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201810450QA SG10201810450QA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201810449XA SG10201810449XA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201810450QA SG10201810450QA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Country Status (19)

Country Link
US (4) US20110269697A1 (zh)
EP (2) EP2321012B1 (zh)
JP (5) JP5933896B2 (zh)
KR (3) KR20180103194A (zh)
CN (2) CN102149432A (zh)
AU (1) AU2009282972A1 (zh)
BR (1) BRPI0918407A2 (zh)
CA (1) CA2734650A1 (zh)
DK (2) DK2321012T3 (zh)
ES (2) ES2703740T3 (zh)
HK (2) HK1254607A1 (zh)
IL (1) IL211153A0 (zh)
MX (1) MX2011001800A (zh)
NZ (1) NZ591181A (zh)
PT (2) PT2321012T (zh)
RU (1) RU2534606C2 (zh)
SG (3) SG10201810449XA (zh)
WO (1) WO2010021928A1 (zh)
ZA (1) ZA201101216B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160304546A1 (en) * 2013-12-05 2016-10-20 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
CN104151397A (zh) * 2014-07-03 2014-11-19 北京大学 一类新型三硫杂二环有机砷化物及其合成方法和在抗肿瘤领域里的应用
JP6413969B2 (ja) * 2015-07-29 2018-10-31 住友金属鉱山株式会社 日射遮蔽体形成用分散液および当該分散液を用いた日射遮蔽体
JPWO2019220961A1 (ja) * 2018-05-18 2020-05-28 ソレイジア・ファーマ株式会社 ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234972A (en) 1880-11-30 William ennis
US761900A (en) 1904-03-05 1904-06-07 Newton Jefferson Norman Flux compound.
US2349729A (en) 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
AU751932B2 (en) 1997-10-15 2002-08-29 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
PT1964557E (pt) 1997-11-10 2013-02-20 Sloan Kettering Inst Cancer Processo para a produção de formulações de trióxido de arsénio
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
AU5391901A (en) 2000-04-26 2001-11-07 Univ Oregon Health Sciences Administration of a thiol-based chemoprotectant compound
DE10132625A1 (de) 2001-07-05 2003-01-23 Oce Printing Systems Gmbh Verfahren, Computerprogrammprodukt und Gerätesystem zum visuellen Überprüfen von Bilddaten
EP2420229A1 (en) * 2002-01-07 2012-02-22 Board Of Regents, University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (zh) 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
WO2007027344A2 (en) 2005-07-29 2007-03-08 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
JP5202332B2 (ja) * 2006-01-13 2013-06-05 ザ テキサス エー アンド エム ユニバーシティ システム がんの治療のための化合物および方法
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
CA2694987A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
ES2392737T3 (es) * 2007-11-02 2012-12-13 Ziopharm Oncology, Inc. Terapia combinada con compuestos arsenicales orgánicos
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
EP3388111A1 (en) 2018-10-17
NZ591181A (en) 2012-09-28
KR20110058818A (ko) 2011-06-01
BRPI0918407A2 (pt) 2015-11-24
SG10201810450QA (en) 2018-12-28
US20210038556A1 (en) 2021-02-11
JP2015120755A (ja) 2015-07-02
RU2534606C2 (ru) 2014-11-27
US20150231107A1 (en) 2015-08-20
HK1212218A1 (zh) 2016-06-10
US20210038557A1 (en) 2021-02-11
EP2321012A4 (en) 2011-10-05
SG10201810449XA (en) 2018-12-28
JP2017002081A (ja) 2017-01-05
DK3388111T3 (da) 2021-12-06
EP3388111B1 (en) 2021-09-29
US11324714B2 (en) 2022-05-10
IL211153A0 (en) 2011-04-28
US10842769B2 (en) 2020-11-24
JP6315841B2 (ja) 2018-04-25
WO2010021928A1 (en) 2010-02-25
CN104800828A (zh) 2015-07-29
RU2011110392A (ru) 2012-09-27
CN102149432A (zh) 2011-08-10
ES2901426T3 (es) 2022-03-22
PT2321012T (pt) 2019-01-11
ES2703740T3 (es) 2019-03-12
AU2009282972A1 (en) 2010-02-25
JP5933896B2 (ja) 2016-06-15
KR20170103023A (ko) 2017-09-12
DK2321012T3 (en) 2018-12-03
KR20180103194A (ko) 2018-09-18
ZA201101216B (en) 2011-10-26
EP2321012A1 (en) 2011-05-18
US20110269697A1 (en) 2011-11-03
JP5976036B2 (ja) 2016-08-23
JP2012500271A (ja) 2012-01-05
JP2014148552A (ja) 2014-08-21
US11324713B2 (en) 2022-05-10
JP2018039853A (ja) 2018-03-15
EP2321012B1 (en) 2018-10-10
CA2734650A1 (en) 2010-02-25
HK1254607A1 (zh) 2019-07-26
MX2011001800A (es) 2011-04-04
PT3388111T (pt) 2021-12-23

Similar Documents

Publication Publication Date Title
PL2303021T3 (pl) Związki do leczenia nowotworu
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
IL213070A0 (en) Methods for the treatment of infections and tumors
HK1159498A1 (zh) 用於治療癌症的方法和組合物
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1212218A1 (zh) 用於治療癌症的有機砷化合物和方法
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
IL226363A0 (en) Compounds and methods for treating cancer
EP2214485A4 (en) METHOD FOR THE TREATMENT OF CANCER
HK1209754A1 (zh) 用於治療癌症的化合物和方法
GB0809046D0 (en) Cancer treatment
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0604114D0 (en) Combinations for the treatment of cancer
GB0712513D0 (en) Treatment of cancer